CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Climb Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$9.73−0.09 (-0.92%)
Close on Oct 19, 2026
- Market cap
- $740.98M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
98.1%
56M of 57M shares
Institutional holders
109
52 new, 22 sold out
Net institutional buying
24M
In Q2 2026
Insider trades, 12 months
3 buys · 6 sales
Net sold $1.87M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC | 6,790,364 | 11.90% | 13G (passive) | Jun 30, 2026 |
| Pontifax VI G.P. L.P. | 5,206,380 | 7.70% | 13G (passive) | Jun 27, 2024 |
| Access Industries Holdings LLC | 3,835,117 | 5.66% | 13D (active) amendment | Oct 3, 2025 |
| Peter Kolchinsky | 23,249,186 | 33.00% | 13D (active) amendment | Jul 2, 2026 |
| RA Capital Management, L.P. | 17,953,284 | 33.00% | 13D (active) amendment | Dec 11, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CLYM | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 11,300,939 | 19.68% | $147.36M | – | 1.28% |
| FMR LLC | 6,790,364 | 11.82% | $88.55M | +6,783,967 | 0.00% |
| UBS Group AG | 3,404,866 | 5.93% | $44.40M | +3,318,921 | 0.01% |
| Braidwell LP | 2,797,375 | 4.87% | $36.48M | +1,267,700 | 1.35% |
| Adage Capital Partners Gp, L.L.C. | 2,506,000 | 4.36% | $32.68M | New | 0.05% |
| BlackRock, Inc. | 2,354,872 | 4.10% | $30.71M | +1,953,223 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 2,127,281 | 3.70% | $27.74K | +210,313 | 0.00% |
| Cormorant Asset Management, LP | 2,106,000 | 3.67% | $27.46M | New | 1.41% |
| Frontier Capital Management Co LLC | 1,939,019 | 3.38% | $25.28M | New | 0.24% |
| Vanguard Capital Management LLC | 1,698,654 | 2.96% | $22.15M | +519,995 | 0.00% |
| Woodline Partners LP | 1,582,291 | 2.75% | $20.63M | New | 0.06% |
| Citadel Advisors LLC | 1,297,972 | 2.26% | $16.93M | +952,309 | 0.00% |
| Redmile Group, LLC | 1,226,330 | 2.14% | $15.99M | New | 1.07% |
| Great Point Partners LLC | 1,000,000 | 1.74% | $13.04M | −334,130 | 2.46% |
| Affinity Asset Advisors, LLC | 972,000 | 1.69% | $12.67M | +272,000 | 0.57% |
| Millennium Management LLC | 908,198 | 1.58% | $11.84M | −368,062 | 0.00% |
| ADAR1 Capital Management, LLC | 822,649 | 1.43% | $10.73M | +224,987 | 0.49% |
| Driehaus Capital Management LLC | 790,000 | 1.38% | $10.30M | +189,054 | 0.06% |
| Geode Capital Management, LLC | 782,199 | 1.36% | $10.20M | +469,200 | 0.00% |
| Stempoint Capital LP | 742,745 | 1.29% | $9.69M | New | 1.67% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 109 | 56M | 98.1% | 52 / 32 | 18 / 22 | 32M | 8M |
| Q1 2026 | 80 | 32M | 56.2% | 27 / 25 | 23 / 10 | 7M | 4M |
| Q4 2025 | 65 | 31M | 54.4% | 17 / 21 | 21 / 18 | 11M | 25M |
| Q3 2025 | 68 | 45M | 77.8% | 12 / 12 | 34 / 13 | 1M | 6M |
| Q2 2025 | 69 | 50M | 86.9% | 19 / 20 | 22 / 26 | 3M | 5M |
| Q1 2025 | 76 | 52M | 90.4% | 11 / 23 | 23 / 14 | 7M | 11M |
| Q4 2024 | 80 | 56M | 97.0% | 27 / 28 | 12 / 18 | 9M | 8M |
| Q3 2024 | 71 | 55M | 95.2% | 32 / 27 | 7 / 7 | 9M | 4M |
| Q2 2024 | 47 | 50M | 86.9% | 31 / 10 | 4 / 5 | 35M | 2M |
| Q1 2024 | 21 | 17M | 29.4% | 1 / 7 | 4 / 3 | 0M | 0M |
| Q4 2023 | 23 | 17M | 29.3% | 3 / 5 | 8 / 3 | 0M | 0M |
| Q3 2023 | 23 | 17M | 29.1% | 2 / 6 | 8 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CLYM | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Small Cap Growth Fund | 1,884,570 | 3.28% | $22.43M | 0.25% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,635,973 | 2.85% | $21.33M | 0.18% | Jun 30, 2026 |
| Fidelity Stock Selector Small Cap Fund | 1,526,300 | 2.66% | $18.16M | 0.25% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,366,686 | 2.38% | $17.82M | 0.00% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 996,400 | 1.73% | $11.86M | 0.54% | Jul 31, 2026 |
| Fidelity Small Cap Growth K6 Fund | 977,590 | 1.70% | $11.63M | 0.25% | Jul 31, 2026 |
| iShares Russell 2000 ETF | 891,234 | 1.55% | $11.62M | 0.01% | Jun 30, 2026 |
| Fidelity Series Small Cap Opportunities Fund | 876,300 | 1.53% | $10.43M | 0.22% | Jul 31, 2026 |
| Columbia Small Cap Growth Fund | 537,698 | 0.94% | $5.89M | 0.16% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 385,723 | 0.67% | $4.59M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 292,463 | 0.51% | $3.81M | 0.00% | Jun 30, 2026 |
| Fidelity Advisor Health Care Fund | 214,022 | 0.37% | $2.55M | 0.08% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 180,178 | 0.31% | $2.35M | 0.02% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 141,772 | 0.25% | $1.85M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Stock Fund | 138,467 | 0.24% | $1.65M | 0.12% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Aoife Brennan | President and CEO, Director | 87,731 | 0.15% | Jun 30, 2026 |
| Susan ALTSCHULLER | Chief Financial Officer | – | – | Jan 8, 2026 |
| Perrin Megan Wilson | Chief Business Officer | – | – | Jan 8, 2026 |
| Cindy Driscoll | Senior Vice President, Finance | – | – | Jan 8, 2026 |
| Emily Pimblett | SVP, Finance & CAO | 18,888 | 0.03% | Jun 20, 2025 |
| Brett Kaplan | Chief Operating Officer | – | – | Jan 15, 2025 |
| RA Capital Nexus Fund II, L.P. | Director | 288,461 | 0.50% | Sep 30, 2026 |
| Capital Healthcare Fund LP RA | Director, 10% owner | 3,403,429 | 5.93% | Sep 30, 2026 |
| Rajeev M. Shah | Director, 10% owner | – | – | Sep 30, 2026 |
| RA Capital Nexus Fund III, L.P. | Director | – | – | Sep 30, 2026 |
| Peter Kolchinsky | Director, 10% owner | 3,396,318 | 5.91% | Sep 30, 2026 |
| RA Capital Nexus Fund, L.P. | Director | 20,000 | 0.03% | Sep 30, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | – | – | Sep 30, 2026 |
| Stephen Basil Thomas | Director | 467,969 | 0.81% | Sep 17, 2026 |
| Breanna Maurine Celebi | Director | – | – | Jul 1, 2026 |
| Andrew David Levin | Director | 0 | – | Jun 8, 2026 |
| Douglas E. Williams | Director | – | – | Jun 8, 2026 |
| Alexander Cumbo | Director | – | – | Jun 8, 2026 |
| Kimberlee C. Drapkin | Director | – | – | Jun 8, 2026 |
| Judith Dunn | Director | – | – | Jun 8, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| RA Capital Nexus Fund, L.P. Director | Sep 28, 2026 | Option exercise | +10,000 | $3.00 | $30.00K | 20,000 |
| RA Capital Nexus Fund, L.P. Director | Sep 28, 2026 | Option exercise | +10,000 | $3.46 | $34.60K | 10,000 |
| RA Capital Nexus Fund, L.P. Director | Sep 28, 2026 | Option exercise | +40,000 | $1.29 | $51.60K | 70,000 |
| RA Capital Nexus Fund, L.P. Director | Sep 28, 2026 | Option exercise | +10,000 | $7.89 | $78.90K | 30,000 |
| Stephen Basil Thomas Director | Sep 15, 2026 | Sale(10b5-1 plan) | −100,000 | $13.67 | $1.37M | 467,969 |
| Aoife Brennan President and CEO, Director | Jun 29, 2026 | Sale(10b5-1 plan) | −30,902 | $13.17 | $406.98K | 87,731 |
| Aoife Brennan President and CEO, Director | Jun 27, 2026 | Option exercise | +68,750 | – | – | 118,633 |
| Stephen Basil Thomas Director | Feb 26, 2026 | Sale(10b5-1 plan) | −16,313 | $7.01 | $114.35K | 154,657 |
| Stephen Basil Thomas Director | Feb 25, 2026 | Sale(10b5-1 plan) | −33,687 | $7.00 | $235.81K | 170,970 |
| Stephen Basil Thomas Director | Feb 13, 2026 | Sale(10b5-1 plan) | −10,000 | $5.81 | $58.10K | 204,657 |
| Stephen Basil Thomas Director | Feb 12, 2026 | Sale(10b5-1 plan) | −90,000 | $5.23 | $470.70K | 214,657 |
| Capital Healthcare Fund LP RA Director, 10% owner | Jan 5, 2026 | Buy | +7,111 | $3.50 | $24.89K | 3,403,429 |
| Peter Kolchinsky Director, 10% owner | Dec 12, 2025 | Buy | +101,462 | $2.86 | $290.18K | 3,396,318 |
| Peter Kolchinsky Director, 10% owner | Dec 11, 2025 | Returned to company | −20,440,000 | – | – | 3,081,757 |
| Peter Kolchinsky Director, 10% owner | Dec 11, 2025 | Buy | +213,099 | $2.18 | $464.56K | 3,294,856 |
| Stephen Basil Thomas Director | Aug 7, 2025 | Award | +100,375 | – | – | 304,657 |
| Aoife Brennan President and CEO, Director | Jun 30, 2025 | Sale(10b5-1 plan) | −20,618 | $1.22 | $25.15K | 48,132 |
| Stephen Basil Thomas Director | Jun 27, 2025 | Option exercise | +25,094 | – | – | 204,282 |
| Aoife Brennan President and CEO, Director | Jun 27, 2025 | Option exercise | +68,750 | – | – | 68,750 |
| Emily Pimblett SVP, Finance & CAO | Jun 20, 2025 | Sale(10b5-1 plan) | −1,242 | $1.24 | $1.54K | 18,888 |
| Emily Pimblett SVP, Finance & CAO | Jun 18, 2025 | Option exercise | +5,000 | – | – | 20,130 |
| Stephen Basil Thomas Director | Mar 27, 2025 | Option exercise | +25,093 | – | – | 179,188 |
| Emily Pimblett SVP, Finance & CAO | Mar 20, 2025 | Sale(10b5-1 plan) | −1,199 | $1.31 | $1.57K | 15,130 |
| Emily Pimblett SVP, Finance & CAO | Mar 18, 2025 | Option exercise | +5,000 | – | – | 16,329 |
| Stephen Basil Thomas Director | Jan 1, 2025 | Option exercise | +50,188 | – | – | 154,095 |
| Emily Pimblett CHIEF ACCOUNTING OFFICER | Dec 19, 2024 | Sale(10b5-1 plan) | −1,235 | $2.02 | $2.49K | 11,329 |
| Emily Pimblett CHIEF ACCOUNTING OFFICER | Dec 18, 2024 | Option exercise | +5,000 | – | – | 12,564 |
| Emily Pimblett CHIEF ACCOUNTING OFFICER | Sep 20, 2024 | Sale(10b5-1 plan) | −1,182 | $8.18 | $9.67K | 7,573 |
| Emily Pimblett CHIEF ACCOUNTING OFFICER | Sep 20, 2024 | Sale(10b5-1 plan) | −9 | $8.06 | $73 | 7,564 |
| Emily Pimblett CHIEF ACCOUNTING OFFICER | Sep 18, 2024 | Option exercise | +5,000 | – | – | 8,755 |
| Valerie Morisset EVP, R&D AND CSO | Jul 22, 2024 | Sale | −30,000 | $7.98 | $239.40K | 31,317 |
| Valerie Morisset EVP, R&D AND CSO | Jul 22, 2024 | Sale | −39,005 | $8.07 | $314.77K | 61,317 |
| Valerie Morisset EVP, R&D AND CSO | Jul 19, 2024 | Sale | −10,201 | $7.09 | $72.33K | 150,322 |
| Valerie Morisset EVP, R&D AND CSO | Jul 19, 2024 | Sale | −50,000 | $7.24 | $362.00K | 100,322 |
| Valerie Morisset EVP, R&D AND CSO | Jul 18, 2024 | Sale | −38,576 | $6.93 | $267.33K | 160,523 |
| Valerie Morisset EVP, R&D AND CSO | Jul 17, 2024 | Sale | −3,207 | $6.91 | $22.16K | 199,099 |
| Valerie Morisset EVP, R&D AND CSO | Jul 16, 2024 | Sale | −50,000 | $7.13 | $356.50K | 202,306 |
| Valerie Morisset EVP, R&D AND CSO | Jul 15, 2024 | Sale | −42,377 | $7.01 | $297.06K | 252,306 |
| Valerie Morisset EVP, R&D AND CSO | Jul 12, 2024 | Sale | −50,000 | $7.07 | $353.50K | 294,683 |
| Valerie Morisset EVP, R&D AND CSO | Jul 11, 2024 | Sale | −50,000 | $7.11 | $355.50K | 344,683 |
| Valerie Morisset EVP, R&D AND CSO | Jul 10, 2024 | Sale | −50,000 | $6.83 | $341.50K | 394,683 |
| Valerie Morisset EVP, R&D AND CSO | Jul 9, 2024 | Sale | −5,931 | $6.66 | $39.50K | 444,683 |
| Valerie Morisset EVP, R&D AND CSO | Jul 5, 2024 | Sale | −12,342 | $7.06 | $87.13K | 450,614 |
| Valerie Morisset EVP, R&D AND CSO | Jul 3, 2024 | Sale | −50,000 | $6.76 | $338.00K | 462,956 |
| Valerie Morisset EVP, R&D AND CSO | Jul 1, 2024 | Option exercise | +7,649 | – | – | 512,956 |
| Peter Kolchinsky Director, 10% owner | Jun 27, 2024 | Buy | +1,059,375 | $3.84 | $4.07M | 2,866,375 |
| Peter Kolchinsky Director, 10% owner | Jun 27, 2024 | Buy | +11,949,171 | $3.84 | $45.88M | 23,521,757 |
| Peter Kolchinsky Director, 10% owner | Jun 27, 2024 | Award | +973,000 | – | – | 11,572,586 |
| Peter Kolchinsky Director, 10% owner | Jun 27, 2024 | Award | +1,807,000 | – | – | 1,807,000 |
| Peter Kolchinsky Director, 10% owner | Jun 27, 2024 | Award | +2,479,872 | – | – | 2,479,872 |
| Stephen Basil Thomas Director | Jun 27, 2024 | Award | +103,907 | – | – | 103,907 |
| Emily Pimblett CHIEF ACCOUNTING OFFICER | Jun 20, 2024 | Sale | −1,245 | $7.21 | $8.98K | 3,755 |
| Emily Pimblett CHIEF ACCOUNTING OFFICER | Jun 18, 2024 | Option exercise | +5,000 | – | – | 5,000 |
| Valerie Morisset EVP, R&D AND CSO | Apr 5, 2024 | Option exercise | +17,847 | – | – | 505,307 |
| Valerie Morisset EVP, R&D AND CSO | Sep 20, 2023 | Option exercise | +5,431 | – | – | 472,163 |
| Valerie Morisset EVP, R&D AND CSO | Sep 20, 2023 | Option exercise | +15,297 | – | – | 487,460 |
| Valerie Morisset EVP, R&D and CSO | Mar 10, 2023 | Option exercise | +61,191 | – | – | 466,732 |
| Valerie Morisset EVP, R&D and CSO | Mar 10, 2023 | Option exercise | +255,219 | – | – | 405,541 |
| RA Capital Nexus Fund II, L.P. Director, 10% owner | Aug 12, 2021 | Conversion | +288,461 | – | – | 288,461 |
| RA Capital Nexus Fund II, L.P. Director, 10% owner | Aug 12, 2021 | Conversion | +4,727,585 | – | – | 7,594,804 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Thomas Stephen Director | Sep 15, 2026 | 100,000 | $1.46M | Sep 15, 2026 | Performance Stock Units |
| Brennan Aoife Officer, Director | Jun 30, 2026 | 30,902 | $406.97K | Jun 29, 2026 | Restricted Stock Unit Vesting |
| Thomas Stephen Director | Feb 25, 2026 | 50,000 | $318.00K | Feb 25, 2026 | Founders Shares |
| Thomas Stephen Director | Feb 12, 2026 | 100,000 | $556.00K | Feb 12, 2026 | Restricted Stock Units |